Downloaded from http://bmjopen.bmj.com/ on February 28, 2016 - Published by group.bmj.com

Open Access

Research

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis Deepson S Shyangdan,1 Olalekan A Uthman,2 Norman Waugh3

To cite: Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 2016;6:e009417. doi:10.1136/bmjopen-2015009417 ▸ Prepublication history and additional material is available. To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015009417). Received 17 July 2015 Accepted 11 November 2015

ABSTRACT Objective: Because of the lack of head-to-head trials, the aim was to indirectly compare sodium glucose transporter-2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. Design: Systematic review and network meta-analysis. Data sources: MEDLINE and EMBASE were searched from January 2005 to January 2015. Eligibility criteria: Randomised controlled trials assessing the efficacy of SGLT-2 inhibitors in patients with type 2 diabetes inadequately controlled with diet and exercise alone or metformin monotherapy. Minimum duration 24 weeks. Indirect comparison was undertaken using Bayesian methods. Results: In monotherapy, a greater proportion of patients achieved a glycated haemoglobin (HbA1c) level of